NCE-1 Intelligence & Market Opportunity

Cibinqo

Abrocitinib

Immunomodulators

Oral Tablet

Approval Date

14-Jan-22

NCE-1 Date

14-Jan-26

NCE Date

14-Jan-27

Commercial snapshot

Market performance & projections

Revenue ($M)

284

CAGR (%)

0.115

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

341

2027

381

2028

412

2029

439

2030

463

2031

486

2032

510

Molecule profile

Details & specifications

Molecule

Abrocitinib

Innovator

PFIZER LABORATORIES DIV PFIZER INC

Dosage Form

Oral Tablet

Strength

200 mg, 50 mg, 100 mg

Therapeutic Category

Immunomodulators

Usage

To treat refractory, moderate-to-severe atopic dermatitis

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.